Document Detail


The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
MedLine Citation:
PMID:  10340838     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The Hypertension Optimal Treatment (HOT) Study had two objectives: (1) to define the optimal target blood pressure when treating hypertensive patients (i.e. the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events. METHODS: The HOT study recruited 18 790 hypertensive subjects aged 50 to 80 years with diastolic blood pressure (DBP) between 100 and 115 mmHg (mean DBP 105 mmHg). Subjects were randomly assigned to be treated with the goal of reaching one of three target DBPs: < or = 90 mmHg (n = 6264), < or = 85 mmHg (n = 6264), or < or = 80 mmHg (n = 6262) using felodipine as initial therapy with the addition of other agents according to a 5-step regimen. In addition, subjects were randomly assigned to receive either 75 mg/day aspirin (n = 9399) or placebo (n = 9391). RESULTS: DBP was reduced by 20.3, 22.3, and 24.3 mmHg in the < or = 90, < or = 85, and < or = 80 mmHg target groups, respectively. The incidence of all major cardiovascular events (fatal and non-fatal stroke, myocardial infarction, and other cardiovascular mortality) decreased, although not significantly, in relation to the randomized target blood pressure. There were 84, 64, and 61 fatal and non-fatal myocardial infarctions in the < or = 90 mmHg, < or = 85 mmHg, and < or = 80 mmHg groups, respectively (P = 0.05). The overall effect of aspirin on cardiovascular events was positive, most noticeably on fatal and non-fatal myocardial infarctions; aspirin reduced events by 36%. There were seven fatal episodes of bleeding (two cerebral) in the aspirin group compared with eight (three cerebral) in the placebo group, and 129 versus 70 non-fatal major episodes of bleeding in the two groups, respectively. The lowest incidence of all major cardiovascular events combined was found at an achieved DBP of 82.6 mmHg and at an achieved systolic blood pressure (SBP) of 138.5 mmHg. In the subgroup with diabetes mellitus at baseline (n = 1501), the effect of intensive lowering of blood pressure was especially noticeable. CONCLUSIONS: Most cardiovascular end-points showed a declining frequency in relation to target blood pressure. The optimal protection against combined major cardiovascular end-points was observed in the range 80-85 mmHg for DBP and in the range 130-140 mmHg for SBP. It is worth noting that 92% of all subjects reached a DBP of < or = 90 mmHg and that side-effects gradually declined from 16.9% at 3 months to 2.2% at the end of the study. A substudy showed that quality of life was linked to the level of blood pressure obtained: the lower the blood pressure, the better the quality of life.
Authors:
L Hansson
Related Documents :
1411248 - Response of diastolic blood pressure to long-term sodium restriction is posture related.
18799948 - Endothelium-dependent vasodilation in relation to different measurements of blood press...
7601438 - Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis.
2338698 - Effects of nitrendipine and atenolol on blood pressure and intracellular sodium in hype...
19265788 - Dietary sodium alters the prevalence of electrocardiogram determined left ventricular h...
6725318 - Patellofemoral contact pressures. the influence of q-angle and tendofemoral contact.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  17     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1999 Feb 
Date Detail:
Created Date:  1999-07-15     Completed Date:  1999-07-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S9-13     Citation Subset:  IM    
Affiliation:
Clinical Hypertension Research, Department of Geriatrics, University of Uppsala, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Aspirin / therapeutic use
Blood Pressure / drug effects*
Cerebrovascular Disorders / etiology,  mortality,  prevention & control
Double-Blind Method
Drug Therapy, Combination
Felodipine / therapeutic use
Humans
Hypertension / complications,  drug therapy*,  physiopathology
Middle Aged
Myocardial Infarction / etiology,  mortality,  prevention & control
Prospective Studies
Survival Rate
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 50-78-2/Aspirin; 72509-76-3/Felodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A call to action for more aggressive treatment of hypertension.
Next Document:  The role of systolic blood pressure in determining risk for cardiovascular disease.